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derma Stem Cell vs Immune Suppression Trial), comparing
HSCT to IV pulse CY is now enrolling patients.
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LONG TERM REMISSION IN SEVERE AND REFRACTORY LUPUS (SLE)
AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION
Arnold, R.1, Massenkeil, G.1, Tamm, I.1, Alexander, T.2, Thiel, A.3,
Radbruch, A.3, Hiepe, F.2 1. Department of Internal Medicine, Hema-
tology/Oncology, Charite´ University Medicine Berlin, Berlin, Germany;
2. Department of Internal Medicine, Rheumatology, Charite´ University
Medicine Berlin, Berlin, Germany; 3. German Rheumatism Research
Centre, Berlin, Germany.
The concept of autologous stem cell transplantation (ASCT) is a
resetting of the immune system. High dose chemotherapy and
immune ablation destroys the immune system (autoreactivity) of
the patient followed by a T cell depleted stem cell transplant with
development of a tolerant immune system. Seven patients (age
19–48 years) with life threatening SLE characterized by severe
organ involvement with persistent active disease despite treatment
with standard immunosuppressive drugs were treated in the Berlin
phase I/II trial since 1998 with a median follow up of 55 (8–90)
months. Treatment includes mobilization of hematopoietic stem
cells with cyclophosphamide (CY) 2 g/m2 and G-CSF (10 ug/kg/
day), leukapheresis and enrichment of CD34 cells, conditioning
with CY 200 mg/kg and rabbit antithymocyte globuline (ATG) 90
mg/kg followed by ASCT. Clinical and serological remission could
be achieved in 7/7 patients. One of 7 patients died due to cerebral
aspergillosis on d  90, 1 patient had a ﬂare at 17 months and died
due to uncontrolled SLE 36 months post ASCT. At the time of
ﬂare change of autoantibody proﬁle occurred and naive Th-cells
and naive B-cells declined compared to the remission patients. Five
patients are alive in clinical remission. These patients are autoan-
tibody negative and no autoreactive Th-cells directed to nucleo-
some could be detected after ASCT. One of these patients gave
birth to a healthy boy 35 months post ASCT. Open questions in
ASCT for treatment of SLE are: Is TRM associated with stage of
disease at ASCT/intensive pretreatment? Why do some patients
relapse? Methods of prevention of relapse after ASCT? In Ger-
many, a multicenter clinical trial protocol is initiated to answer
these questions.
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VIRAL INFECTIONS DURING CD34 CELLS PURIFIED AUTOLOGOUS
PERIPHERAL BLOOD STEM CELL TRANSPLANTATION FOR THE TREAT-
MENT OF REFRACTORY AUTOIMMUNE DISEASES
Nagafuji, K.1, Tsukamoto, H.1, Numata, A.1, Miyamoto, T.2,
Harada, M.1 1. First Department of Internal Medicine, Kyushu Uni-
versity Hospital, Fukuoka, Japan; Center for Cellular and Molecular
Medicine, Kyushu University Hospital, Fukuoka, Japan.
Aims: We retrospectively analyzed viral infections during
CD34 cells autologous peripheral blood stem cell transplantation
(PBSCT) for the treatment of refractory autoimmune diseases
(AD). Materials and Methods: 9 cases of systemic sclerosis (SSc)
with interstitial pneumonia(IP),1 case of amyopathic dermatomy-
ositis (ADM) with IP, 1 case of Wegener granulomatosis (WG)
with exophthalmous. Except one SSc patient No. 9, all patients had
been treated with steroid, and were administered with steroid
during peri-transplant period. PBSC were mobilized with cyclo-
phosphamide (CY) 4 g/m2G-CSF, and CD34 cells were puri-
ﬁed with CliniMACS. Pre-transplant conditioning consisted of CY
200 mg/kg. Acyclovir (ACV) 250 mg/day was administered from
day1 to day 35. Result: Before PBSC mobilizations, patient No. 2
with ADM was positive for cytomegalovirus (CMV) antigenemia
and treated with gancyclovir (GCV). After PBSC mobilizations, 3
patients became positive for CMV antigenemia (3/11 27%) treated
with GCV, and 1 patient developed genital herpes simplex virus
infection treated with ACV. After transplantations, 5 out of 11
patients (45%) became positive for CMV antigenemia treated with
GCV. Median day becoming positive for CMV antigenemia was
22.5 days post-transplant ranging 10 to 38 days. Two patients,
No.1 and No. 8 (18%), developed adenoviral hemorrhagic cystitis
(adeno HC) on day 64 and day 33, respectively, treated with
cidofovir (CDV).Discussion: Before transplantations, most of AD
patients had received immunosuppressive therapy. CD34 cells
PBSCT is an immunosuppressive therapy. Thus, during peri-
transplant period, AD patients developed various viral infections.
Infection surveillance and diagnostic work-up, same as with those
used in allogeneic recipients seem to be necessary (Table1).
Patient
No.
Age/
Sex Diseases
Pre-
mobilization
Steroid Tx
Pre-
mobilization
Viral
Infections
Post-
mobilization
Viral
Infections
Post-
transplant
Viral
Infection
1 54/F SSc/IP yes day 38
CMV,
day 64
adeno
HC
2 54/F ADM/IP yes CMV CMV day 21
CMV
3 55/M SSC/IP yes CMV
4 58/M SSc/Ip yes day 10
CMV
5 54/F SSc/IP yes day 24
CMV
6 53/F SSC/IP yes
7 21/M WG yes
8 49/F SSc/IP yes CMV day 31
adeno
HC, day
33 CMV
9 33/F SSc/IP no
10 63/F SSc/IP yes genital HSV
11 61/F SSc/IP yes CMV day 21
CMV
AUTOLOGOUS
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TARGETED TOTAL MARROW IRRADIATION USING 3D IMAGE GUIDED
TOMOGRAPHIC INTENSITY MODULATED RADIATION THERAPY: AN
ALTERNATIVE TO STANDARD TBI
Wong, J.Y.C.1, Liu, A.1, Schultheiss, T.1, Popplewell, L.1, Stein, A.1,
Rosenthal, J., Forman, S.1, Somlo, G.1 City of Hope Cancer Center,
Duarte, CA.
Purpose: TBI is an important part of many hematopoietic stem
cell transplant (HSCT) conditioning regimens. Dose escalation of
TBI has been difﬁcult due to associated organ toxicities. A method
to deliver a more targeted dose of TBI to sites of greatest tumor
burden is needed to reduce dose to normal organs, reduce toxici-
ties, and permit dose escalation. The purpose of this study was to
evaluate the delivery of targeted myeloablative doses of radiation to
bone and marrow using a recently developed image guided tomo-
graphic intensity modulated radiation therapy delivery system (to-
motherapy). Methods: CT data sets from 3 patients (2 AML and
1 multiple myeloma) were used for dosimetry planning studies to
evaluate two strategies: total marrow irradiation (TMI), where the
target region was deﬁned as the skeletal bone, and total marrow
and lymphoid irradiation (TMLI), where the target regions were
deﬁned as bone, major lymph node chains, liver, spleen, and sanc-
tuary sites, such as brain. Organ doses and dose distributions were
compared to conventional TBI. Results: A 1.7 to 7.5-fold reduc-
tion in median organ dose was observed with TMI and TMLI
compared to conventional TBI. Dose-volume histogram analysis
predicted for the potential to escalate dose to bone and marrow up
to 20 Gy with TMI, while maintaining doses to normal organs at
lower levels compared to conventional TBI to 12 Gy (Table).
Results were similar for the adult and pediatric patients indicating
that this method will be applicable to most patients regardless of
frame size. TMI to 10 Gy was delivered as part of an autologous
tandem transplant regimen to the patient with multiple myeloma.
Clinical results conﬁrmed treatment planning predictions. After
TMI, the patient experienced the expected blood count nadir,
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followed by successful engraftment. Grade 2 nausea and grade 1
emesis were seen brieﬂy on day 2 of TMI. Skin erythema, oral
mucositis, esophagitis, and enteritis were not observed. Conclu-
sions:This report demonstrates the feasibility to selectively deliver
myeloablative doses of radiation to bone and marrow using To-
motherapy. Organ doses were substantially lower than those asso-
ciated with standard TBI and predict for the potential to signiﬁ-
cantly reduce associated toxicities, allowing for dose escalation.
Ongoing trials will deﬁne the maximum TMI/TMLI doses achiev-
able and deﬁne the potential advantages and limitations of this new
approach for patients undergoing HSCT (Table1).
Median Organ Doses (Gy) for TMI 12 and 20 Gy vs Standard TBI
12 Gy in a 20 Year Old Patient with AML
Organ TMI 12 Gy TMI 20 Gy Standard TBI 12 Gy
Lungs 4.3 6.8 8.8
Esophagus 3.9 5.6 12.4
Liver 6.0 8.7 12.3
Kidneys 5.6 8.7 12.2
Bowel 3.5 5.0 12.3
Bladder 7.0 7.4 12.4
Eyes 6.6 7.0 11.3
Parotids 3.9 4.8 11.8
Oral cavity 2.2 3.0 11.8
Stomach 3.1 5.0 12.2
Ovaries 4.3 6.0 12.3
Breasts 6.9 8.7 11.5
Heart 6.2 6.4 12.1
Thyroid 3.7 4.9 12.1
Brain 4.0 7.9 12.0
Lens 1.5 1.9 11.3
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ABSOLUTE NUMBER OF TRANSPLANTED CD34 CELLS EXPRESSING
C-MPL (CD110) CORRELATES WITH SPEED OF PLATELET ENGRAFT-
MENT FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION
Sartor, M.M.1, Antonenas, V.2, Garvin, F.2, Bradstock, K.F.2,
Gottlieb, D.J.2 1. Flow Cytometry Unit, Westmead Hospital., Sydney,
NSW, Australia; 2. Sydney Cellular Therapies Laboratory, Westmead
Hospital, Sydney, NSW, Australia.
Recovery of neutrophil numbers after peripheral blood stem cell
transplantation (PBSCT) is closely associated with graft CD34
cell dose. Predicting the speed of platelet recovery is more difﬁcult
but would be of value given that a signiﬁcant minority of patients
experience delayed platelet recovery and bleeding complications
after transplantation. In this study we retrospectively analysed the
graft composition of 29 patients who underwent autologous trans-
plantation, using blood stem cells mobilized with cyclophoshamide
and G-CSF, to assess the utility of c-mpl expression on CD34
cells as a predictor of platelet engraftment (ie, time to platelet
count greater than 20  109/L for 3 consecutive days without the
need for platelet transfusion). Absolute CD34 cells and CD34
subsets expressing c-mpl were enumerated using a published single
platform viable CD34 ﬂow cytometry assay (BMT, 2005). Of the
29 patients 7 required at least 21 days for platelet engraftment.
These patients received a median graft dose of 5.7  104
CD34CD110 cells/kg compared with a median dose of 13.4 
104 cells/kg received by patients who experienced platelet engraft-
ment within 21 days of transplant (P .013). In contrast, there was
no difference in the number of CD34 cells/kg infused (4.0 v 4.9
106/kg for 	 or  21 days for platelet engraftment respectively,
P  .23). There was a poor correlation between the absolute
number of CD34 cells and the number of CD34CD110 cells
in the graft (r2  0.48). Similarly there was no correlation between
the percentage of CD34 cells expressing c-mpl and the speed of
platelet engraftment (8.1 v 5.8%) for 	 or  21 days for platelet
engraftment respectively, P  .39). Patients with 	21 days for
platelet engraftment received platelet transfusions more often than
those with 21 days for platelet engraftment (median 9 v 2 trans-
fusions, P  .001). The absolute number of CD34/CD110
cells/kg infused at time of transplantation appears to be an impor-
tant factor identifying patients at risk of delayed (	21 days) platelet
engraftment. Those with 6  104CD34/CD110cells/kg are at
particularly high risk of delayed platelet engraftment requiring
multiple transfusion after transplantation.
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AMD3100  G-CSF IMPROVES HEMATOPOIETIC PROGENITOR CELL
(HPC) COLLECTION IN PATIENTS WITH HODGKIN’S DISEASE (HD)
Cashen, A.F.1, Devine, S.1, Vij, R.1, DiPersio, J.1 Washington Uni-
versity School of Medicine, St. Louis, MO.
For patients undergoing autologous stem cell transplantation, the
number of CD34 cells infused is a reliable predictor of neutro-
phil and platelet engraftment, with doses 5  106 CD34
cells/kg associated with faster count recovery. However, among the
98 patients with HD who have undergone G-CSF-alone mobili-
zation at our institution in the past 5 years, 22% did not achieve a
minimum HPC collection of 2  106 CD34 cells/kg in 5
apheresis procedures, and only 15% achieved a collection 5 
106 CD34 cells/kg. AMD3100 mobilizes HPCs by reversibly
inhibiting the interaction of CXCR4 and SDF-1
. It has been
shown to improve HPC mobilization in patients with multiple
myeloma and non-Hodgkin’s lymphoma. Here we present results
for the ﬁrst ten HD patients treated with a mobilization regimen of
AMD3100  G-CSF. Ten patients with relapsed (8) or refractory
(2) HD were mobilized with G-CSF (10 ug/kg/day)  AMD3100
(240 ug/kg/day) beginning on day 4. Apheresis was performed 11
hours after each AMD3100 dose. The ﬁrst dose of AMD3100
produced a median (range) 3.0 (1.9–5.1)-fold increase in the num-
ber of circulating CD34 cells. Six patients achieved a collection
of 5  106 CD34 cells/kg, and all patients collected 	2  106
CD34 cells/kg (range, 3.6–9.4). The median (range) number of
apheresis procedures performed per patient was 2 (1–4). No grade
II-IV adverse events were ascribed to AMD3100. All patients have
been transplanted with G-CSF AMD3100 mobilized cells. They
have had prompt and stable engraftment, with median neutrophil
recovery at day9 (9–11) and median platelet recovery at day16
(12–23). We conclude that AMD3100G-CSF is a well-tolerated
and effective mobilization regimen in patients with HD. All pa-
tients (100%, 95% CI 69%–100%) mobilized with AMD3100 
G-CSF achieved the minimum collection of 2  106 CD34
cells/kg, and a signiﬁcantly higher proportion of patients (60%,
95% CI 26%–88%) achieved the goal collection of  5  106
CD34 cells/kg than did the historical controls (15%). Impor-
tantly, the median collection in the ﬁrst two days of pheresis was
5.4  106 CD34 cells/kg, which is signiﬁcantly better than
historical controls, who collected a median 3.0  106 CD34
cells/kg in the ﬁrst two days of pheresis (P  .014). Our results
demonstrate that the mobilization regimen of AMD3100  G-
CSF can improve the number of HPCs collected and decrease the
number of days of pheresis in HD patients.
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HEMATOPOIETIC AC133 STEM CELL THERAPY FOR PATIENTS WITH
SEVERE PERIPHERAL VASCULAR DISEASE
Statkute, L.1, Oyama, Y.1, Pearce, W.1, Yaung, K.1, Villa, M.1,
Shook, T.1, Clifton, R.1, Verda, L.1, Krosnjar, N.1, Burt, R.K.1 Division
of Immunotherapy, Department of Medicine, Northwestern University
Feinberg School of Medicine, Chicago, IL.
Hematopoietic stem cells, especially more primitive endothelial
cell precursors, AC133 cells, may contribute to neo-angiogene-
sis. Here we report short-term outcomes of the ﬁrst 5 patients who
underwent autologous selected AC133 stem cell percutaneous
transplant for their medically refractory and not-amenable to sur-
gical reconstruction lower extremity (LE) peripheral vascular dis-
ease (PVD). Patients were 3 females and 2 males; median age was
59 (range 26–84) years old. Peripheral blood AC133 cells were
mobilized with G-CSF 10 mcg/kg/day for 4 days. Median aphere-
sis number of was 1 (range 1 to 2). AC133 cells were enriched
using CliniMACS device, Miltenyi Biotec, Inc. Total number of
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